QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abattis Bioceuticals Corp. stock logo
ATTBF
Abattis Bioceuticals
$0.00
$0.00
$0.00
N/AN/A11,650 shsN/A
Neuralstem, Inc. stock logo
CUR
Neuralstem
$5.07
-23.2%
$1.06
$1.10
$13.78
$10.65M1.81236,278 shs316,168 shs
Regis Co. stock logo
RGS
Regis
$5.41
-1.6%
$8.23
$5.41
$28.00
$12.34M1.7122,869 shs7,443 shs
TNGN
Tengion
$0.00
$0.00
$0.00
N/AN/A6,051 shs10,000 shs
TRSBF
3SBio
$0.80
$0.80
$0.80
$0.80
N/AN/A63,275 shsN/A
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abattis Bioceuticals Corp. stock logo
ATTBF
Abattis Bioceuticals
0.00%0.00%0.00%0.00%0.00%
Neuralstem, Inc. stock logo
CUR
Neuralstem
-23.18%+24.57%+1,270.27%+856.60%+171.12%
Regis Co. stock logo
RGS
Regis
-3.51%-21.43%-28.76%-41.11%-72.77%
TRSBF
3SBio
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Abattis Bioceuticals Corp. stock logo
ATTBF
Abattis Bioceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Neuralstem, Inc. stock logo
CUR
Neuralstem
N/AN/AN/AN/AN/AN/AN/AN/A
Regis Co. stock logo
RGS
Regis
0.0328 of 5 stars
0.00.00.03.11.30.00.0
TNGN
Tengion
N/AN/AN/AN/AN/AN/AN/AN/A
TRSBF
3SBio
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Abattis Bioceuticals Corp. stock logo
ATTBF
Abattis Bioceuticals
N/AN/AN/AN/A
Neuralstem, Inc. stock logo
CUR
Neuralstem
N/AN/AN/AN/A
Regis Co. stock logo
RGS
Regis
N/AN/AN/AN/A
TNGN
Tengion
N/AN/AN/AN/A
TRSBF
3SBio
N/AN/AN/AN/A

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Abattis Bioceuticals Corp. stock logo
ATTBF
Abattis Bioceuticals
N/AN/AN/AN/AN/AN/A
Neuralstem, Inc. stock logo
CUR
Neuralstem
$260K40.95N/AN/A$6.64 per share0.76
Regis Co. stock logo
RGS
Regis
$233.33M0.05N/AN/A($16.12) per share-0.34
TNGN
Tengion
N/AN/AN/AN/AN/AN/A
TRSBF
3SBio
N/AN/AN/AN/AN/AN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Abattis Bioceuticals Corp. stock logo
ATTBF
Abattis Bioceuticals
N/A-$0.16N/AN/AN/AN/AN/AN/AN/A
Neuralstem, Inc. stock logo
CUR
Neuralstem
-$4.93MN/A0.00N/A-39,417.64%-170.51%-110.16%N/A
Regis Co. stock logo
RGS
Regis
-$7.39M-$1.77N/AN/AN/A-1.97%N/A-1.13%5/1/2024 (Estimated)
TNGN
Tengion
N/AN/A0.00N/AN/AN/AN/AN/AN/A
TRSBF
3SBio
N/AN/A0.00N/AN/AN/AN/AN/A

Latest RGS, TNGN, TRSBF, CUR, and ATTBF Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
1/31/202412/31/2023
Regis Co. stock logo
RGS
Regis
-$1.19-$0.43+$0.76-$1.29$52.94 million$51.05 million      

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Abattis Bioceuticals Corp. stock logo
ATTBF
Abattis Bioceuticals
N/AN/AN/AN/AN/A
Neuralstem, Inc. stock logo
CUR
Neuralstem
N/AN/AN/AN/AN/A
Regis Co. stock logo
RGS
Regis
N/AN/AN/AN/AN/A
TNGN
Tengion
N/AN/AN/AN/AN/A
TRSBF
3SBio
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Abattis Bioceuticals Corp. stock logo
ATTBF
Abattis Bioceuticals
N/AN/AN/A
Neuralstem, Inc. stock logo
CUR
Neuralstem
N/A
2.53
2.53
Regis Co. stock logo
RGS
Regis
N/A
0.31
0.30
TNGN
Tengion
N/AN/AN/A
TRSBF
3SBio
N/AN/AN/A

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Abattis Bioceuticals Corp. stock logo
ATTBF
Abattis Bioceuticals
32.45%
Neuralstem, Inc. stock logo
CUR
Neuralstem
38.30%
Regis Co. stock logo
RGS
Regis
31.50%
TNGN
Tengion
N/A
TRSBF
3SBio
N/A

Insider Ownership

CompanyInsider Ownership
Abattis Bioceuticals Corp. stock logo
ATTBF
Abattis Bioceuticals
N/A
Neuralstem, Inc. stock logo
CUR
Neuralstem
5.38%
Regis Co. stock logo
RGS
Regis
1.60%
TNGN
Tengion
N/A
TRSBF
3SBio
N/A

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Abattis Bioceuticals Corp. stock logo
ATTBF
Abattis Bioceuticals
N/AN/AN/ANot Optionable
Neuralstem, Inc. stock logo
CUR
Neuralstem
62.10 millionN/ANot Optionable
Regis Co. stock logo
RGS
Regis
3972.28 million2.24 millionOptionable
TNGN
Tengion
147,000N/AN/ANot Optionable
TRSBF
3SBio
5,311N/AN/ANot Optionable

RGS, TNGN, TRSBF, CUR, and ATTBF Headlines

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Abattis Bioceuticals logo

Abattis Bioceuticals

OTCMKTS:ATTBF
Abattis Bioceuticals Corp. operates as a life sciences and biotechnology company in Canada. The company develops and licenses natural health products, medicines, extractions, and ingredients for the biological, nutraceutical, bioceutical, and cosmetic markets. It also provides Comfort, a cannabinoid enhanced nutraceutical for pain and inflammation; and Health-Canada licensed services for the cannabis industry. The company was formerly known as Abattis Biologix Corporation and changed its name to Abattis Bioceuticals Corporation in September 2012. Abattis Bioceuticals Corp. was incorporated in 1997 and is headquartered in Vancouver, Canada.
Neuralstem logo

Neuralstem

NASDAQ:CUR
Neuralstem, Inc., a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The company's stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. Its lead product candidate is NSI-189, a chemical entity, which has been completed Phase II clinical trial for the treatment of major depressive disorder, as well as is in preclinical study for the treatment-refractory depression, Angelman Syndrome, Alzheimer's disease, ischemic stroke, diabetic neuropathy, irradiation-induced cognitive deficit, and long-term potentiation enhancement. The company also develops NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease; Phase II clinical trial for the treatment of chronic ischemic stroke; and Phase I clinical trials for the treatment of chronic spinal cord injury, as well as is in preclinical study for the traumatic brain injury. In addition, it develops NSI-532, which is in preclinical study for treatment of Alzheimer's disease; and NSI-777 that is in preclinical study for treatment of human demyelinating diseases. Neuralstem, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.
Regis logo

Regis

NYSE:RGS
Regis Corporation owns and franchises hair care salons in North America. The company operates through two segments, Franchise Salons and Company-Owned Salons. Its salons provide haircutting; styling, including shampooing and conditioning; hair coloring; and other services, as well as sells various hair care and other beauty products. The company also operates accredited cosmetology schools. It operates its salons primarily under the SmartStyle, Supercuts, Cost Cutters, Roosters, First Choice Haircutters, and Magicuts concepts names. Regis Corporation was founded in 1922 and is headquartered in Minneapolis, Minnesota.

Tengion

OTCMKTS:TNGN
Tengion, Inc. is a medicine company, focuses on discovering, developing, manufacturing and commercializing of neo-organs and products. The company was founded by Steven Nichtberger and David I. Scheer on July 10, 2003 and is headquartered in Winston-Salem, NC.

3SBio

OTCMKTS:TRSBF
3SBio Inc., an investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; Cipterbin, an anti-HER2 monoclonal antibody for the treatment of HER2-positive metastatic breast cancer in combination with chemotherapy; Interferon, a human interferon a2a for injection; and Inleusin, for the treatment of renal cell carcinoma, melanoma, thoracic fluid build-up caused by cancer and tuberculosis. It also offers YISAIPU, the receptor-antibody fusion tumor necrosis factor inhibitor; Mendi-minoxidil tincture, an OTC external medicine for treating hair loss; EPIAO and SEPO, an erythropoietin injection; SPARIN, an injectable low-molecular-weight heparin calcium; and Xenopax, a recombinant humanized anti-cd25 monoclonal antibody injection for prevention of acute rejection after renal transplantation. In addition, the company provides TPO-105 Pediatric ITP; SSS12 Cinacalcet hydrochloride; SSS13 Sevelamer carbonate; 301S TNFR-Fc protein; AP506 Apremilast; SSS32 Tofacitinib; and MN709 Minoxidil Foam. Further, the company provides trading, project management and consultation, technology, sports, financial, investment advisory, and agricultural services. It has collaboration agreements with companies, such as Toray Industries Inc, and Toray. The company was founded in 1993 and is headquartered in Shenyang, the People's Republic of China.